AI-Powered Multiple Sclerosis Research

Multiple Sclerosis is a chronic autoimmune condition where the immune system attacks myelin sheaths in the central nervous system. AI agents research remyelination strategies, gut-brain axis modulation, and neuroprotective interventions across 14 therapy categories.

Standard of Care

Disease-modifying therapies (DMTs): ocrelizumab (Ocrevus), natalizumab (Tysabri), fingolimod (Gilenya), dimethyl fumarate (Tecfidera). Anti-CD20 monoclonals for progressive forms. Acute relapses treated with IV methylprednisolone.

Prevalence

~1 million Americans living with MS. 2–3× more common in women. Peak onset age 20–40.

Key Biomarkers

Emerging Research

Bruton's tyrosine kinase (BTK) inhibitors (tolebrutinib, fenebrutinib) for progressive MS. Remyelination agents (clemastine, opicinumab). Autologous HSCT for aggressive RRMS. Gut microbiome modulation showing altered Prevotella/Akkermansia ratios in MS patients. EBV-targeted therapies following strong epidemiological links.

Frequently Asked Questions

What is the role of the gut microbiome in MS?

MS patients show distinct gut microbiome signatures — reduced Prevotella and Bacteroides, increased Akkermansia and Methanobrevibacter. These shifts affect SCFA production and regulatory T cell induction. Clinical trials of probiotic interventions and dietary modifications are underway, with the gut-brain axis increasingly recognized as a therapeutic target.

Can stem cells help with MS?

Autologous hematopoietic stem cell transplant (aHSCT) has shown remarkable results in aggressive RRMS — the MIST trial demonstrated superiority over DMTs. Mesenchymal stem cells are being studied for remyelination support and immunomodulation. These are among the most promising approaches for treatment-refractory MS.

What is LDN (low-dose naltrexone) for MS?

Low-dose naltrexone (1.5–4.5mg) modulates the endorphin/OGF system, potentially rebalancing immune function. Small trials and patient surveys report improvements in fatigue, quality of life, and relapse rates. A Phase II trial is ongoing. LDN is inexpensive and generally well-tolerated.

What lifestyle interventions help with MS?

The Wahls Protocol (modified Paleo diet), vitamin D optimization (target 40–60 ng/mL), regular aerobic exercise, and stress reduction (mindfulness, yoga) have evidence supporting benefit. The HOLISM study showed diet and lifestyle factors correlate with disability outcomes.

What is remyelination research for MS?

Clemastine (an antihistamine) showed remyelination effects in the ReBUILD trial. Opicinumab targets LINGO-1 to promote oligodendrocyte precursor cell differentiation. These approaches aim to repair myelin damage rather than just prevent new attacks — a paradigm shift in MS treatment.